Biotechnology

Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.

GEN (Genetic Engineering & Biotechnology News) Sophia Ktori

Genetic Barcoding Reveals How Pre-Bone Marrow Transplant Conditioning Impacts Immune System Regeneration

Researchers used genetic barcoding to track human blood-forming stem and progenitor cells transplanted into mice, revealing how the different cell types regenerate the blood and immune system, and how different forms of pretransplant conditioning affected blood and immune cell recovery.

Read at GEN (Genetic Engineering & Biotechnology News)

BioPharma Dive Delilah Alvarado

Roche breast cancer pill cleared by FDA

Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.

Read at BioPharma Dive

STAT Biotech Elaine Chen

STAT+: Flagship opens biotech-creation outpost in the U.K.

Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:

Read at STAT Biotech

BioPharma Dive Kristin Jensen

AI drugmaker Isomorphic restocks with $5B fundraise

Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.

Read at BioPharma Dive

GEN (Genetic Engineering & Biotechnology News) Julianna LeMieux, PhD

Mapping the Hidden Viral Communities of the Human Gut Microbiome

Researchers identified over 116,000 gut viral groups, revealing previously unknown relationships between viruses, bacteria, and metabolism, with findings offering new insights into gut health and irritable bowel syndrome (IBS).

Read at GEN (Genetic Engineering & Biotechnology News)

STAT Biotech Adam Feuerstein

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.

Read at STAT Biotech

BioPharma Dive Gwendolyn Wu

Marrow sets out to challenge genetic medicines for severe blood diseases

Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.

Read at BioPharma Dive

STAT Biotech Jason Mast

STAT+: With $173 million, new startup takes aim at sickle cell

Researchers are seeking a sickle cell treatment as effective as gene therapy, without the drawbacks. This entrepreneur thinks he might have one.

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: After death in gene therapy trial for a brain disease, progress is reported

An unexpected patient death rattled researchers who sought to pierce the blood-brain barrier. Now some think they have a better way of mitigating risks.

Read at STAT Biotech

GEN (Genetic Engineering & Biotechnology News) Savannah Wiegel

Enhancer-Targeted CRISPR Turns Up Healthy Gene Copy in Autism Organoid Model

In lab-grown human neurons and organoids carrying CHD8 or SCN2A mutations, researchers reduced organoid overgrowth and moved neuronal electrical activity closer to wild-type levels.

Read at GEN (Genetic Engineering & Biotechnology News)

NASA Science Space

Biotechnology, Spacesuit Work, and Dragon Packing Start Week Aboard Station

Biotechnology research including growing human lung cells and managing blood flow in space awaited the Expedition 75 crew on Monday. Spacesuit checks, cargo packing, and Earth observations rounded out the busy schedule aboard the International Space Station at the beginning of the week.

Read at NASA Science

GEN (Genetic Engineering & Biotechnology News) Kathy Vuksanaj

Toward Connected Laboratory Ecosystems

In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Sophia Ktori

Gut Microbome and Bile Acid Modification Linked with Longevity

Researchers studying how gut microbes modify bile acids have identified changes in the metabolic activity of the gut microbiome associated with exceptional longevity in humans, and found that amplifying the same activity with engineered bacteria improved metabolic health in aged mice.

Read at GEN (Genetic Engineering & Biotechnology News)

STAT Biotech Margaret Manto

STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC

The supplement NAC has been widely available for years, but exists in a legal gray area.

Read at STAT Biotech

BioPharma Dive Jonathan Gardner

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.

Read at BioPharma Dive

AWS Machine Learning Blog Elias Bedmar SI

Novo Nordisk modernizes manufacturing process documents with Amazon Bedrock AgentCore

Novo Nordisk's Manufacturing Technology team within the Tablet area team built a process-intelligence assistant on Amazon Bedrock AgentCore, using a GraphRAG architecture that pairs a knowledge graph in Amazon Neptune with hybrid search in Amazon OpenSearch Serverless to turn millions of controlled manufacturing documents into grounded, cited answers.

Read at AWS Machine Learning Blog

BioPharma Dive Ben Fidler

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.

Read at BioPharma Dive

BioPharma Dive Delilah Alvarado

J&J bets $2.2B on Ollin’s vision loss drug

The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

Read at BioPharma Dive

STAT Biotech Meghana Keshavan

STAT+: Biotech’s rebound isn’t lifting all boats equally

Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions

A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence

CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.

Read at STAT Biotech

BioPharma Dive Ben Fidler

Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

Lilly’s 15th announced company acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.

Read at BioPharma Dive

GEN (Genetic Engineering & Biotechnology News) Uduak Thomas

Single-Cell Method Reveals On- and Off-Target Effects of Cas9 Edits on Gene Expression

A new method called Superb-seq pairs Cas9 editing with single-cell RNA sequencing to show which edits, including off-target ones, occur in each cell and how they alter gene expression, offering a clearer view of genome editing’s potential consequences.

Read at GEN (Genetic Engineering & Biotechnology News)

STAT Biotech Jason Mast

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.

Read at STAT Biotech

BioPharma Dive

The infrastructure decisions that will enable tomorrow’s biggest breakthroughs

Faster drug discovery depends on more than the model. What drug developers need to know about AI.

Read at BioPharma Dive

BioPharma Dive Kayt Leonard, Global Director, SAS

Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment

As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.

Read at BioPharma Dive

BioPharma Dive

Completing the circle: the next evolution in sustainable pharmaceutical blister packaging

Discover how innovative PET and PP lidding are advancing sustainable pharmaceutical blister packaging.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

Big-name investors pour $100M into DNA therapeutics developer Seawolf

The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.

Read at BioPharma Dive

STAT Biotech Damian Garde

BeOne, Hengrui top list of China’s most powerful drugmakers

A new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.

Read at STAT Biotech

BioPharma Dive Gwendolyn Wu

One of Europe’s leading VCs banks a €725M ‘crossover’ fund

Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.

Read at BioPharma Dive

Older stories